MARTIN FRAZEE: Open Payments
NPI 1548824089 · WOBURN, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,019 in 163 payments from 18 companies in 2025. Trend: 2023 $321 · 2024 $3,667 · 2025 $4,019
Food & beverage: $3,975Education: $44
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $911 |
| ABBVIE INC. | 17 | $466 |
| Alkermes, Inc. | 15 | $377 |
| Otsuka America Pharmaceutical, Inc. | 13 | $359 |
| Lundbeck LLC | 11 | $332 |
| Neurocrine BioSciences, Inc. | 11 | $273 |
| Vanda Pharmaceuticals Inc. | 18 | $249 |
| E.R. Squibb & Sons, L.L.C. | 7 | $166 |
| Braeburn Inc. | 10 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $140 |
Products named: CAPLYTA, REXULTI, VRAYLAR, INGREZZA, FANAPT, ARISTADA, COBENFY, BRIXADI.
Industry payments across MA — which companies pay providers there.
